NIR178X
Total Payments
$461,684
Transactions
33
Doctors
8
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $391,395 | 28 | 8 |
| 2017 | $70,289 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $461,684 | 33 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 2 MULTI CENTER OPEN LABEL STUDY OF NIR178 IN IN PATIENTS WITH CYSTIC FIBROSIS COMBINATION WITH PDR001 IN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS AND NON-HODGKIN LYMPHOMA | Novartis Pharmaceuticals Corporation | $428,939 | 0 |
| A PHASE 2 MULTI CENTER OPEN LABEL STUDY OF NIR178 IN IN PATIENTS WITH CYSTIC FIBROSIS COMBINATION WITH PDR001 IN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS AND NON-HODGKIN LYMPHOMA | NOVARTIS PHARMACEUTICALS CORPORATION | $26,044 | 0 |
| PHASE I IB TRIAL OF PDR001 PLUS PBF 509 FOR PATIENTS WITH ADVANCED NSCLC | Novartis Pharmaceuticals Corporation | $3,472 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,150 | 4 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $1,079 | 8 |
Top Doctors Receiving Payments for NIR178X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $458,456 | 17 |
| , M.D | Molecular Genetic Pathology | Tampa, FL | $672.36 | 3 |
| , MD, MS | Internal Medicine | Tampa, FL | $672.36 | 3 |
| , MD | Internal Medicine | Tampa, FL | $672.36 | 3 |
| Tawee Tanvetyanon | Hematology & Oncology | Tampa, FL | $672.36 | 3 |
| , MD | Internal Medicine | Tampa, FL | $134.82 | 1 |
| Charles Williams | — | Tampa, FL | $134.82 | 1 |
| , MD | Internal Medicine | Tampa, FL | $134.82 | 1 |
| , MD | Internal Medicine | Tampa, FL | $134.82 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $433,490
- NOVARTIS PHARMACEUTICALS CORPORATION $28,194
Product Information
- Type Drug
- Total Payments $461,684
- Total Doctors 8
- Transactions 33
About NIR178X
NIR178X is a drug associated with $461,684 in payments to 8 healthcare providers, recorded across 33 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $391,395 was paid across 28 transactions to 8 doctors.
The most common payment nature for NIR178X is "Unspecified" ($461,684, 100.0% of total).
NIR178X is associated with 5 research studies, including "A PHASE 2 MULTI CENTER OPEN LABEL STUDY OF NIR178 IN IN PATIENTS WITH CYSTIC FIBROSIS COMBINATION WITH PDR001 IN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS AND NON-HODGKIN LYMPHOMA" ($428,939).